`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`MYLAN PHARMACEUTICALS INC., CELLTRION, INC., and
`APOTEX, INC.,
`Petitioners,
`
`v.
`REGENERON PHARMACEUTICALS, INC.,
`Patent Owner.
`
`
`Inter Partes Review No.: IPR2021-008801
`
`
`U.S. Patent No. 9,669,069 B2
`Filed: December 17, 2015
`Issued: June 6, 2017
`Inventor: George D. Yancopoulos
`
`Title: USE OF A VEGF ANTAGONIST TO TREAT
`ANGIOGENIC EYE DISORDERS
`
`
`Petitioner’s Amended Mandatory Notices
`
`
`1 IPR2022-00257 and IPR2022-00301 have been joined with this proceeding.
`
`
`
`
`
`Mylan Pharmaceuticals Inc. (“Petitioner”) submits the following amended
`
`mandatory notices to identify additional related matters.
`
` REAL PARTIES-IN-INTEREST (37 C.F.R. § 42.8(b)(1)).
`Viatris Inc. and Mylan Inc. are parent companies of Petitioner Mylan
`
`Pharmaceuticals Inc.
`
` Accordingly, Viatris Inc., Mylan Inc., and Mylan
`
`Pharmaceuticals Inc. are identified as real parties-in-interest to the current Petition.
`
`Momenta Pharmaceuticals, Inc. and Janssen Research & Development LLC are
`
`wholly-owned
`
`subsidiaries of
`
`Johnson &
`
`Johnson, a publicly held
`
`company. Momenta Pharmaceuticals, Inc., Janssen Research & Development LLC,
`
`and Johnson & Johnson are also real parties-in-interest to the current Petition. No
`
`other parties exercised or could have exercised control over this Petition; no other
`
`parties funded, directed and controlled this Petition. See Trial Practice Guide, 77
`
`Fed. Reg. 48759-60 (Aug. 14, 2021).
`
` RELATED MATTERS (37 C.F.R. § 42.8(b)(2)) (AMENDED).
`Petitioner identifies Mylan Pharms. Inc. v. Regeneron Pharms., Inc., No.
`
`IPR2021-00881 (P.T.A.B.), filed concurrently herewith. Petitioner also identifies
`
`Mylan Pharms. Inc. v. Regeneron Pharms., Inc., No. IPR2022-01225 (P.T.A.B.) and
`
`Mylan Pharms. Inc. v. Regeneron Pharms., Inc., No. IPR2022-01226 (P.T.A.B.).
`
`To the best of Petitioner’s knowledge, there are no other judicial or administrative
`
`matters that would affect, or be affected by, a decision in this proceeding;
`
`
`
`nonetheless, out of an abundance of caution, Petitioner further identifies Chengdu
`
`Kanghong Biotechnology Co. v. Regeneron Pharms., Inc., No. PGR2021-00035
`
`(P.T.A.B.).
`
`U.S. Patent Nos. 10,130,681 B2, 10,857,205 B2, 10,828,345 B2, and
`
`10,888,601 B2; and U.S. Patent Application Nos. 17/072,417, 17/112,063,
`
`17/112,404, 17/350,958, and 17/352,892 claim the benefit of the ’069 patent filing
`
`date.
`
` LEAD AND BACK-UP COUNSEL AND SERVICE INFORMATION (37
`C.F.R. § 42.8(b)(3)-(4)).
`Petitioner identifies its lead and backup counsel below.
`
`Lead
`
`Back-Up
`
`Paul J. Molino (Reg. No. 45,350)
`paul@rmmslegal.com
`
`Postal and Hand Delivery Address
`Rakoczy Molino Mazzochi Siwik LLP
`6 West Hubbard Street
`Chicago, IL 60654
`Telephone: (312) 222-6300
`Facsimile: (312) 843-6260
`
`Petitioner consents to email service at:
`MYL_REG_IPR@rmmslegal.com
`
`
`William A. Rakoczy
`(admitted pro hac vice)
`wrakoczy@rmmslegal.com
`
`Deanne M. Mazzochi (Reg. No. 50,158)
`dmazzochi@rmmslegal.com
`
`Heinz J. Salmen
`(admitted pro hac vice)
`hsalmen@rmmslegal.com
`
`Jeff A. Marx (Reg. No. 56,977)
`jmarx@rmmslegal.com
`
`Eric R. Hunt
`(admitted pro hac vice)
`ehunt@rmmslegal.com
`
`
`2
`
`
`
`Neil B. McLaughlin (Reg. No. 70,810)
`nmclaughlin@rmmslegal.com
`
`L. Scott Beall (Reg. No. 52,601)
`sbeall@rmmslegal.com
`
`Thomas H. Ehrich (Reg. No. 67,122)
`tehrich@rmmslegal.com
`
`Steven J. Birkos (Reg. No. 65,300)
`sbirkos@rmmslegal.com
`
`Postal and Hand Delivery Address
`Rakoczy Molino Mazzochi Siwik LLP
`6 West Hubbard Street
`Chicago, IL 60654
`Telephone: (312) 222-5127
`Facsimile: (312) 843-6260
`
`
`
`
`Please direct all correspondence to lead and back-up counsel at the contact
`
`information above.
`
` Petitioner also consents
`
`to service by email at:
`
`MYL_REG_IPR@rmmslegal.com.
`
`
`
`
`
`
`
`3
`
`
`
`Dated: July 18, 2022
`
`
`
`
`
`
`
`
`
`
`Respectfully Submitted,
`
`RAKOCZY MOLINO MAZZOCHI SIWIK LLP
`
`/Paul J. Molino/
`Paul J. Molino
`Registration No. 45,350
`6 West Hubbard Street
`Chicago, IL 60654
`Telephone:
`(312) 222-6300
`Facsimile:
`(312) 843-6260
`paul@rmmslegal.com
`
`
`Counsel for Petitioner
`
`
`
`
`
`4
`
`
`
`
`
`CERTIFICATE OF SERVICE
`The undersigned hereby certifies that a true and correct copy of the foregoing
`
`Petitioner’s Amended Mandatory Notices was served on July 18, 2022, via
`
`electronic mail by agreement of the parties, to the following counsel for record of
`
`Patent Owners:
`
`Deborah E. Fishman (Reg. No. 48,621)
`David A. Caine (Reg. No. 52,683)
`Arnold & Porter Kaye Scholer LLP
`3000 El Camino Real
`Five Palo Alto Square, Suite 500
`Palo Alto, California 94306-3807
`Telephone: 650.319.4519
`Telephone: 650.319.4710
`Facsimile: 650.319.4573
`Deborah.Fishman@arnoldporter.com
`David.Caine@arnoldporter.com
`RegeneronEyleaIPRs@arnoldporter.com
`
`Alice S. Ho (Lim. Rec. No. L1162)
`Victoria Reines
`Jeremy Cobb
`Arnold & Porter Kaye Scholer LLP
`601 Massachusetts Ave., N.W.
`Washington D.C. 20001
`Tel: 202.942.5000
`Fax: 202.942.5999
`Alice.Ho@arnoldporter.com
`Victoria.Reines@arnoldporter.com
`Jeremy.Cobb@arnoldporter.com
`
`Respectfully Submitted,
`
`RAKOCZY MOLINO MAZZOCHI SIWIK LLP
`
`/Paul J. Molino/
`
`Daniel Reisner
`Matthew M. Wilk
`Arnold & Porter Kaye Scholer LLP
`250 West 55th Street
`New York, New York 10019-9710
`Telephone: 212.836.8000
`Fax: 212.836.8689
`Daniel.Reisner@arnoldporter.com
`Matthew.Wilk@arnoldporter.com
`
`
`Dated: July 18, 2022
`
`
`
`
`
`
`